Report Calls for More Scrutiny in FDA Drug Approvals

The U.S. Food and Drug Administration should be more transparent when granting accelerated approval for certain drugs, the Institute for Clinical and Economic Review, an influential drug pricing body, said in a report Thursday.

Related articles

You may also be interested in

Headline

Never Miss A Story

Get our Weekly recap with the latest news, articles and resources.
Cookie policy

We use our own and third party cookies to allow us to understand how the site is used and to support our marketing campaigns.